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Carbonic anhydrase IX (CAIX) is a hypoxia-regulated and tumor-speciﬁc protein that maintains the pH
balance of cells. Targeting CAIX might be a valuable approach for speciﬁc delivery of cytotoxic drugs,
thereby reducing normal tissue side-effects. A series of dual-target compounds were designed and
synthesized incorporating a sulfonamide, sulfamide, or sulfamate moiety combined with several
different anti-cancer drugs, including the chemotherapeutic agents chlorambucil, tirapazamine, and
temozolomide, two Ataxia Telangiectasia and Rad3-related protein inhibitors (ATRi), and the anti-
diabetic biguanide agent phenformin. An ATRi derivative (12) was the only compound to show a
preferred efﬁcacy in CAIX overexpressing cells versus cells without CAIX expression when combined
with radiation. Its efﬁcacy might however not solely depend on binding to CAIX, since all described
compounds generally display low activity as carbonic anhydrase inhibitors. The hypothesis that dual-
target compounds speciﬁcally target CAIX expressing tumor cells was therefore not conﬁrmed. Even
though dual-target compounds remain an interesting approach, alternative options should also be
investigated as novel treatment strategies.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ad3 related inhibitor; CAIX,
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Solid tumors are characterized by a hypoxic microenvironment
caused by their immature and inadequate vascular supply of oxy-
gen and nutrients. These hostile hypoxic conditions result in a
phenotype that is associated with a worse prognosis [1] and
resistance to standard treatment options such as radiotherapy,
chemotherapy, and surgery [2] [3], and [4]. Several different ap-
proaches are currently being investigated to target these hypoxic
areas to make tumors more sensitive to standard treatment mo-
dalities [5] [6], and [7].
Carbonic anhydrase IX (CAIX) can be a valuable therapeutic
target since it plays an important role in maintaining the intracel-
lular pH homeostasis [8] and [9]. Furthermore its expression isarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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lated via the hypoxia-inducible factor (HIF) pathway [11]. Even
though alternative pathways are also able to modulate CAIX
expression [12] [13], and [14], its signiﬁcant prognostic value in
many different tumor types [15] has promoted investigations in its
use as an imaging agent for diagnostic and prognostic purposes [5]
[16], [17] [18], and [19]. Together these characteristics of CAIX
support investigations into the therapeutic targeting of CAIX to
improve efﬁcacy of standard treatments. The function of CAIX is
evolutionary conserved and catalyzes the hydration of carbon di-
oxide to bicarbonate at the cell membrane. The bicarbonate is
transported back intracellular from the extracellular space,
whereas the free proton is extruded in the extracellular space. CAIX
thereby maintains the balance between an acidic extracellular and
alkaline intracellular pH of tumor cells, the latter of which would
otherwise acidify due to the increased acid production resulting
from their glycolytic metabolism [8] and [9]. Many different in-
hibitors are currently being developed to speciﬁcally target the
tumor-associated CAIX isoform and have shown promise in
reducing tumor cell survival, migration, invasion, and reduce tumor
xenograft growth and metastases formation [20] [21], [22], and
[23]. Furthermore, the combination therapy of CAIX inhibitors
(CAIXi) with standard treatment options was previously found to
increase the efﬁcacy of radiotherapy [24] and of weakly basic
chemotherapeutic agents such as doxorubicin [25].
The predominant expression of CAIX on hypoxic tumor cells can
also be exploited to direct cytotoxic agents speciﬁcally to those
CAIX expressing cancer cells thereby possibly minimizing normal
tissue toxicity. This can be achieved by conjugating anti-cancer
drugs with CAIX inhibiting molecules that bind to the Zn2þ active
site of CAIX and hence inhibit its enzymatic function [8] [26], andScheme 1. Reagents and conditions: (i) (COCl)2, D
Scheme 2. Reagents and conditions: (i) MeOH, DCM; (ii)
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previously that such a dual-target approach with a sulfamide CAIXi
moiety coupled to the radiosensitizing compound nitroimidazole to
be a more effective radiosensitizer than an indanesulfonamide
CAIXi [28]. Alternative novel dual-target compounds have been
developed to investigate this strategy of dual-targeting further in
the context of anti-cancer agents to target CAIX. Here we have
designed ﬁve different classes of dual-target compounds conju-
gated to CAIXi (sulfonamide, sulfamide, or sulfamate), which
included the chemotherapeutic anti-cancer agents chlorambucil,
tirapazamine, and temozolomide, two ataxia telangiectasia and
Rad3-related protein inhibitors (ATRi), and the biguanide agent
phenformin, previously used in diabetes treatment. We hypothe-
size that these new dual-target compounds will have the ability to
speciﬁcally target CAIX expressing cells and modulate their efﬁcacy
in a CAIX-dependent manner.
2. Results and discussion
2.1. Chemistry
Chlorambucil was converted to its acid chloride [29] 1 by using
oxalyl chloride. This chlorambucil acid chloride reacted with
different benzene sulfonamides under basic condition to obtain
good yields of chlorambucil derivatives 2a, 2b and 2c. Chlorambucil
carbamate derivatives were obtained by converting compound 1
into a methyl ester [30] using methanol. This ester was reduced to
alcohol [31], i.e. compound 3, after treating with lithium aluminium
hydride. Compound 3 was treated with triphosgene to obtain its
respective chloroformate [32], i.e. compound 4 (Scheme 2). The
reaction of chlorambucil chloroformate (4) with different benzeneMF, DCM, 0 Cert; (ii) DIPEA, THF, 0 Cert.
LAH, THF; (iii) Triphosgene, Na2CO3, Toluene, DMF.
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Tirapazamine derivatives 8 and 11were synthesized from 6 and
9 with the previously described procedure [33]. In short, 6 and 9
reacted with 4-(2-aminoethyl) benzene sulfonamide under reﬂux
conditions and was followed by oxidation of the mono-oxides
(Scheme 4).
The ATRi derivatives 12 and 13 were synthesized from
commercially available VE-821 and VE-822 (MedChemTronica)
using a classical synthetic strategy described previously [25]
(Scheme 5).
Commercially purchased temozolomide (SelleckChem) was
converted into its respective acid by treating with concentrated
sulfuric acid and sodium nitrate at 0 Ce15 C (Scheme 6) [34].
Reacting the temozolomic acid with different benzenesulfona-
mides, aminoxysulfonamide [35] and 5-amino-1, 3,4-thiadiazole-2-
sulfonamide hydrochloride under known amide bond formation
conditions [34] resulted in compounds 15a, 15b, 15c and 15d
(Scheme 7).
The compound 18 was obtained by a slight modiﬁcation based
on the method reported by Kelarev et al. [36]. The commercially
available compounds 4-(2-aminoethyl) benzenesulfonamide 16Scheme 3. Reagents and conditions: (i) DIPEA, THF, 0 Cert.
Scheme 4. Reagents and conditions: (i) RNH2 (3 e
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chiometric amount of hydrochloric acid (Scheme 8).
2.2. Binding afﬁnity human CAs
Increased binding afﬁnity to human carbonic anhydrases (CAs)
as comparedwith their respective parental compound are observed
(Table 1) for most of the compounds, except for the CAIXi conju-
gated ATRi (12 and 13), which do not bind to any of the four tested
human CA isoforms included (Ki > 50000 nM). The Ki values of the
other dual-targeting compounds are higher than of the previously
reported CAIXi [20] with 15a showing relatively good Ki for the CAII
and CAIX isoforms, but not for CAXII. Only the phenformin deriv-
ative 18was found to be selective for the transmembrane CAIX and
CAXII isoforms. To investigate whether the biological efﬁcacy of the
functionalized compounds is dependent on CAIX expression,
canine kidney epithelial (MDCK) cells without CAIX (CAIX), i.e.
both human and canine [37], or MDCK cells transfected with hu-
man CAIX [37], i.e. overexpressing CAIX (CAIXþ), were used.
Western blotting conﬁrmed differential expression of CAIX in these
cells both under normoxic and hypoxic conditions (Supplementary
Fig. S1).
2.3. Chlorambucil derivatives
Chlorambucil (4-[p-[bis(2-chloroethyl)amino]phenyl]butyric
acid) is a nitrogen mustard that acts as a bifunctional alkylating
agent used for decades to treat cancers originating in the blood and
lymphatic system, e.g. chronic lymphocytic leukemia and lym-
phomas [38]. Even though reported data suggest chlorambucil ef-
ﬁcacy to increase in an acidic microenvironment [39], the CAIXi
moiety (benzenesulfonamides) with different linkers (i.e. amide,
carbamate) might allow for speciﬁc targeting of the compounds to
these areas in the tumor. The six CAIXi conjugated chlorambucil
derivatives (2a, 2b, 2c, 5a, 5b, and 5c, Schemes 1 and 2) lead to
reduced cell viability as compared to the parental compound,quiv.), DME, reﬂux; (ii) TFAA, H2O2, DCM, rt.
elivering cytotoxic drugs towards CAIX expressing cells: A concept of
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Scheme 5. Reagents and conditions: (i) ClSO2NCO, tBuOH, NEt3, DCM, 0 C to rt; (ii) 20% TFA-DCM.
Scheme 6. Reagents and conditions: (i) Con. H2SO4, NaNO2, 0 Ce15 C.
Scheme 7. Reagents and conditions: (i) BOP, NEt3, DCM, rt.
Scheme 8. Reagents and conditions:
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Fig. S1). The therapeutic efﬁcacy of these compounds however
was not increased in the CAIXþ MDCK cells as compared with the
CAIX MDCK cells. Furthermore, none of the six compounds
showed an increased efﬁcacy upon hypoxia exposure (0.2% O2). In
contrast, some of the chlorambucil dual-target derivatives were
less cytotoxic (i.e. higher IC50, Table 2) in CAIX expressing cells in-
dependent of oxygen levels, which contradicts the studies
demonstrating an increased efﬁcacy of chlorambucil in an acidic
micromilieu [39]. All together from these results it can be
concluded that the CAIXi conjugated chlorambucil derivatives do
not show an increased efﬁcacy in a CAIX or hypoxia dependent
manner.
2.4. Tirapazamine derivatives
The hypoxia-activated prodrug tirapazamine (3-amino-1,2,4-
benzotriazine-1,4-dioxide) has been tested in several clinical tri-
als in combination with chemo- and/or radiotherapy [40]. The
cytotoxicity of tirapazamine results from activation by reductive
enzymes that add an electron to the parent drug to produce a
radical species that causes DNA damage. Nevertheless, no deﬁnitive
conclusions regarding its clinical efﬁcacy can be drawn since
addition of tirapazamine to standard treatment (i.e. radio-
chemotherapy) did not result in an increased beneﬁt in phase III
clinical trials. In addition, tirapazamine treatment was often char-
acterized by toxic side-effects, such as nausea, vomiting, and diar-
rhea, which limited its therapeutic gain [40]. Targeting
tirapazamine towards the CAIX expressing (hypoxic) areas in tu-
mors by conjugating tirapazamine with the benzenesulfonamide
CAIXi might thereby prove a valuable approach to reduce normal
tissue toxicity and increase the efﬁcacy of the compounds (8 and
11) in CAIX expressing (hypoxic) cells. Cell viability assays (Table 2,
Supplementary Fig. S2) conﬁrmed that the parental compound was
speciﬁcally effective in hypoxic cells, and more effective in CAIX(i) 6.0 M HCl aq, nBuOH, reﬂux.
elivering cytotoxic drugs towards CAIX expressing cells: A concept of
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Table 1
Binding afﬁnity (Ki) to human CAI, CAII, CAIX, and CAXII of the parental compounds (bold) and their CAIXi conjugated derivatives.
Compound Ki (nM)a Selectivity Ratiosb
hCA I hCA II hCA IX hCA XII Ki hCA II/Ki hCA IX Ki hCA II/Ki hCA XII
Chlorambucil >50000 >50000 >50000 >50000
2a 73.0 9.0 172 689 0.05 0.01
2b 5950 747 8970 7340 0.08 0.10
2c 8400 450 4610 10160 0.10 0.04
5a 5580 553 2740 9380 0.20 0.06
5c 6140 265 4130 9570 0.06 0.03
5c 5670 504 3850 13600 0.13 0.04
Tirapazamine >50000 >50000 >50000 >50000
8 567 7.1 383 14600 0.02 <0.01
11 428 8.1 307 624 0.03 0.01
Temozolomide >50000 >50000 >50000 >50000
15a 91.3 9.2 37.1 9300 0.25 <0.01
15b >50000 >50000 >50000 >50000
15c 539 90.5 271 12400 0.33 0.01
15d 743 15.7 176 92.7 0.09 0.17
ATRi VE-821 >50000 >50000 >50000 >50000
12 >50000 >50000 >50000 >50000
ATRi VE-822 >50000 >50000 >50000 >50000
13 >50000 >50000 >50000 >50000
Phenformin >50000 >50000 >50000 >50000
18 4435 501 20.2 1.7 24.8 295
Acetazolamidec 250 12.1 25.3 5.7 0.48 2.12
a Values reported (in nM) are the average of three different estimations with errors between 5 and 10% of the reported values. Reported values > 50000 indicates no binding
of the compound towards the CA isoforms.
b Selectivity ratios of the cytosolic hCAII over the tumor-associated hCAIX and hCAXII isoforms.
c Non-speciﬁc CAi acetazolamide is included as a reference.
Table 2
Estimated IC50 of the cytotoxic parental compounds (bold) and their CAIXi conju-
gated derivatives obtained with cell viability assays for MDCK CAIX and MDCK
CAIXþ cells exposed to normoxic and hypoxic conditions.
Compound Normoxia (mM)a Hypoxia (mM)a
CAIX- CAIXþ CAIX- CAIXþ
Chlorambucilb 93 >100 ~100 >100
2a ~100 87 ~100 95
2b 18 98 14 92
2c 18 ~100 18 ~100
5a 8 56 8 62
5b 86 98 52 100
5c 89 99 81 ~100
Tirapazaminec >300 >300 <50 95
8 >300 >300 ~300 >300
11 >300 >300 >300 >300
Temozolomided 775 >1000 ~1000 >1000
15a >1000 >1000 >1000 >1000
15b 719 >1000 ~1000 >1000
15c >1000 >1000 >1000 >1000
15d >1000 >1000 >1000 >1000
a No IC50 reached is indicated with >. Estimated IC50 value higher than the
maximum concentration included is indicated with ~.
b Included concentrations for chlorambucil were 1, 10, and 100 mM.
c Included concentrations for tirapazamine were 50, 100, 200, and 300 mM.
d Included concentrations for temozolomide were 100, 400, 700, and 1000 mM.
S.J.A. van Kuijk et al. / European Journal of Medicinal Chemistry xxx (2016) 1e12 5cells (IC50 < 50 versus 95 mM, p ¼ 0.037). The CAIXi conjugated
tirapazamine derivatives however abrogated the effect observed
for the parental compound, both during hypoxia and normoxia,
which was independent of CAIX levels (Table 2).2.5. Temozolomide derivatives
The current treatment of glioblastoma is based on radiotherapy
combined with temozolomide, which has been shown to increase
survival in phase III clinical trials [41]. Temozolomide is a methyl-
ating agent that spontaneously hydrolyzes to its active metabolitePlease cite this article in press as: S.J.A. van Kuijk, et al., New approach of d
dual-target drugs, European Journal of Medicinal Chemistry (2016), http3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) at physi-
ological pH [42]. The acidic extracellular pH in tumors might
therefore reduce spontaneous temozolomide conversion and
thereby decrease its efﬁcacy. Inhibiting CAIX function is known to
decrease extracellular acidiﬁcation in vitro [24] [25], [28], and [43]
and we hypothesized that conjugating temozolomide with a sul-
fonamide or sulfamate moiety (15a, 15b, 15c, and 15d) will specif-
ically target hypoxic tumors and increase temozolomide
conversion and thereby its efﬁcacy. Nevertheless, while temozo-
lomide resulted in lower cell viability in CAIX cells, consistent
with the pH-dependent mechanism of activation, the CAIXi con-
jugated temozolomide derivatives 15a, 15c, and 15d were ineffec-
tive in reducing cell viability in both MDCK cell lines during
normoxic and hypoxic conditions within the concentration range
tested in the present study (Table 2, Supplementary Fig. S3). In
contrast, 15b was similarly effective as the parental temozolomide
compound (Table 2).
This dual-target compound was therefore investigated further
in clonogenic survival assays in which the medium of the cells was
acidiﬁed because of CAIX function during hypoxic conditions
(Supplementary Fig. S1) [44]. Temozolomide was again more
effective in reducing clonogenic cell survival in the CAIX MDCK
cells as comparedwith the CAIXþMDCK cells (Fig.1), similarly to its
efﬁcacy on cell viability. During hypoxia however temozolomide
caused no difference in clonogenic survival as compared to nor-
moxia, even though hypoxia is required to activate CAIX and cause
extracellular acidiﬁcation [43] and [45] and is therefore hypothe-
sized to reduce temozolomide conversion and efﬁcacy. In contrast,
the CAIXi conjugated derivative 15b signiﬁcantly reduced clono-
genic cell survival in hypoxic versus normoxic conditions in the
CAIXþ cells (surviving fraction is 46.1 ± 3.1 versus 26.1% ±7.9 during
normoxia and hypoxia respectively, p < 0.05). Nevertheless, the
effect of 15b on survival was not signiﬁcantly different from the
parental temozolomide compound. In addition, the low binding
afﬁnity of the compound (Table 1) combined with its relatively low
efﬁcacy in the CAIXþ as compared to the CAIX cells minimizes itselivering cytotoxic drugs towards CAIX expressing cells: A concept of
://dx.doi.org/10.1016/j.ejmech.2016.10.037
Fig. 1. Clonogenic cell survival of conﬂuent MDCK CAIX and CAIXþ cells during
normoxia (21% O2) and hypoxia (0.2% O2) when exposed to temozolomide (TMZ) and
the CAIXi conjugated derivative 15b. Surviving fraction (%) was normalized to vehicle
control. Average ± SEM of three independent biological repeats is shown. Asterisks
indicate statistical signiﬁcance (*p < 0.05; ***p < 0.001).
Fig. 2. Relative cell viability (%) in MDCK CAIX and CAIXþ cells exposed to ATR in-
hibitors (VE-821 and VE-822) or the CAIXi conjugated derivatives (12 and 13) in
combination with radiation during normoxia (21% O2) and anoxia (0.02% O2). Nor-
moxic cells were irradiated with 2 Gy and anoxic cells with 4 Gy to induce similar
effects on cell viability. Cells were exposed to 500 nM VE-821 and 12, and to 50 nM VE-
822 and 13. Average ± SEM of three independent biological repeats is shown. Asterisks
indicate statistical signiﬁcance (*p < 0.05; **p < 0.01; ***p < 0.001).
S.J.A. van Kuijk et al. / European Journal of Medicinal Chemistry xxx (2016) 1e126potential for further development. These results furthermore sug-
gest that temozolomide efﬁcacy is not affected by CAIX dependent
changes in extracellular pH during hypoxia. A reduction of temo-
zolomide conversion and efﬁcacy might require lower pH levels, i.e.
pH < 6.6, which may have not been achieved in the present ex-
periments [8] [9], and [39].2.6. ATR inhibitor derivatives
Preclinical experiments have shown that Ataxia Telangiectasia
and Rad3-related protein inhibitors (ATRi) reduce the DNA repair
capacity resulting in enhanced cell death and decreased tumor
growth when combined with either chemo- or radiotherapy [46]
[47], and [48]. However ATRi are not highly tumor speciﬁc, thus
targeting these compounds towards the CAIX expressing areas of a
tumor might increase their therapeutic beneﬁt. The effect on cell
viability of the parental ATRi (VE-821 and VE-822) and their CAIXi
conjugated derivatives (12 and 13) was tested in combination with
radiotherapy to induce DNA damage where a higher radiation dose
was applied to anoxic cells, since those are more radioresistant [49]
and [50]. The parental ATRi and the CAIXi conjugated derivatives in
combination with radiation decreased cell viability as compared to
radiation only in the CAIXþ cells (p < 0.05) under both normoxic
and anoxic conditions, but not in the CAIX cells (Fig. 2). The only
exception is the derivative 13, which had no signiﬁcant effect on
cell viability during anoxic conditions in both cell lines as compared
to radiation alone (p ¼ 0.09 and p ¼ 0.08 for CAIX and CAIXþ cells,
respectively). More importantly, the CAIXi conjugated derivative 12
wasmore effective than its respective parental ATRi (VE-821) in thePlease cite this article in press as: S.J.A. van Kuijk, et al., New approach of d
dual-target drugs, European Journal of Medicinal Chemistry (2016), httpCAIXþ (p < 0.01 during normoxia and anoxia), but not the CAIX
cells (p ¼ 0.52 and p ¼ 0.72 for normoxia and anoxia, respectively),
suggesting a CAIX speciﬁc effect. In contrast, the CAIXi conjugated
derivative 13 in combination with radiation was less effective in
reducing cell viability than the parental compound VE-822 in
CAIXþ cells (p < 0.001 and p < 0.01 during normoxic and anoxic
conditions, respectively). Although radiation induced similar ef-
fects on cell viability during normoxic and anoxic conditions, the
efﬁcacy of derivative 12 did not increase further during anoxic
conditions as compared to normoxic conditions, even though CAIX
expression is upregulated under hypoxic conditions
(Supplementary Fig. S1) and these conditions are essential for CAIXi
binding [43] and [45]. Although derivative 12 indeed proved to be
more effective in CAIXþ than in CAIX cells in combination with
radiation, its efﬁcacy might however not be solely dependent on
binding to CAIX, which is consistent with unfavorable Ki values of
the compound (Table 1). Exposing both cell lines to ATRi without
irradiation decreased cell viability of both cell lines during nor-
moxic and anoxic conditions, although this effect appeared to be
slightly more pronounced in the CAIX cells (Supplementary
Fig. S5). Differences in ATRi response between the cell lines when
combined with radiation might be explained by a lower number of
cells in the resistant S-phase of the cell cycle [51], or by a decreased
DNA repair capacity in cells with lower intracellular pH [52] [53],
and [54], i.e. those that do not express CAIX. This may also explain
the difference in sensitivity to cytotoxic drugs between both cell
lines, although further investigations are required to prove thiselivering cytotoxic drugs towards CAIX expressing cells: A concept of
://dx.doi.org/10.1016/j.ejmech.2016.10.037
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2.7. Phenformin derivatives
Phenformin (1-(diaminomethylidene)-2-(2-phenylethyl)guani-
dine) is a drug used to treat diabetes, but was withdrawn from the
North-American market in the 1970s by the Food and Drug
Administration (FDA) due to a high risk of developing lactic acidosis
[55]. Treating patients with a similar but less potent drug metfor-
minwas found to be associated with a decrease in cancer incidence
and an increased life span of cancer patients [56]. The repurposing
of these compounds as anti-cancer agents is therefore being
investigated where phenformin is found to be more lipophilic,
thereby requiring less active transport than metformin [57]. The
proposed mechanism of action of phenformin is its ability to inhibit
mitochondrial respiration, which will consequently result in a
decreased ATP production, thereby reducing tumor cell growth and
improving tumor oxygenation as a result of decreased oxygen
consumption [58] and [59]. Conjugating phenformin with CAIXi
might make the drug more tumor-speciﬁc leading to reduced
normal tissue toxicity. Since tumor cells are more sensitive to
phenformin treatment due to their altered energy metabolism,
human colorectal HCT116 cells, with or without CAIX knockdown
[24] and [28] were used to study the effect of phenformin and its
CAIXi conjugated derivative 18 on mitochondrial respiration.
Western blotting conﬁrms low expression of CAIX in CAIX KD cells
under hypoxic conditions as compared with control cells
(Supplementary Fig. S1B). As expected, CAIX levels were low in
both cell lines under normoxic conditions. Phenformin signiﬁcantly
reduced Oxygen Consumption Rate (OCR) in both cell lines
(p < 0.05), independent of CAIX expression levels (Fig. 3). In
contrast, the CAIXi conjugated derivative 18 was ineffective in
reducing OCR, evenwhen a fourfold higher concentrationwas used.
3. Conclusion
Overall our hypothesis that newly designed dual-target drugs
are more selective for CAIX expressing cells and are able to
modulate their own efﬁcacy by inhibiting CAIX function was not
conﬁrmed. Of all derivatives included, only one (i.e. the ATRi de-
rivative 12) proved more effective than its parental compound
when combined with irradiation in CAIXþ cells versus CAIX cells.
Nevertheless, the effect of this compound may not only be related
to binding of the compound to CAIX due to limited binding afﬁnityFig. 3. Oxygen Consumption Rate (OCR) of HCT116 cells with CAIX (shSCR) or without
CAIX expression (shCAIX) exposed to phenformin or the CAIXi conjugated derivative
18. OCR was normalized to baseline OCR levels before compound injection.
Average ± SEM of four independent biological repeats is shown. Asterisks indicate
statistical signiﬁcance (*p < 0.05).
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ditions. The rest of the derivatives included in this study did not
show an increased efﬁcacy in CAIXþ versus CAIX cells, or an efﬁ-
cacy that depended on oxygen levels, i.e. hypoxia versus normoxia.
Nevertheless, since the parental compounds proved effective in
these experiments the conjugation of the CAIXi moiety with the
cytotoxic compounds may have caused conformational changes,
thereby altering the compounds efﬁcacy. In addition, these
conformational changes may have also limited the binding of the
CAIXi moiety (sulfonamide, sulfamide or aminoxysulfonamide)
into the Zn2þ containing active pocket of CAIX, which explains the
lack of CAIX speciﬁcity and binding afﬁnity for human CAs (Table 1)
of the compounds. Alternative strategies to target the CAIX
expressing cells in a tumor, e.g. antibody targeting or an increased
number of CAIXi conjugated molecules [60], might therefore be
more promising options to pursue in the future.
4. Experimental section
4.1. Chemistry
4.1.1. General
Unless otherwise speciﬁed, reagents and solvents were of
commercial quality and were used without further puriﬁcation. All
reactions were carried out under an inert atmosphere of nitrogen.
TLC analyses were performed on silica gel 60 F254 plates (Merck
Art.1.05554). Spots were visualized under 254 nm UV illumination,
or by ninhydrin solution spraying. Melting points (mp) were
determined on a Büchi Melting Point 510 and are uncorrected. 1H
and 13C NMR spectra were recorded on Bruker DRX-400 spec-
trometer using DMSO-d6 as a solvent and tetramethylsilane as an
internal standard. For 1H NMR spectra, chemical shifts are
expressed in d (ppm) downﬁeld from tetramethylsilane, and
coupling constants (J) are expressed in Hertz. Electron Ionization
mass spectra were recorded in positive or negative mode on a
Waters MicroMass ZQ. All compounds that were tested in the
biological assays were analyzed by High-resolution ESI mass
spectra (HRMS) using on a Q-ToF I mass spectrometer ﬁtted with an
electrospray ion source in order to conﬁrm the purity of >95%.
4.1.2. 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoyl chloride (1)
Oxalyl chloride (32.8 mmol, 2.0 equiv.) was added slowly over a
period of 1.0 h at 5e10 C to a stirred solution of chlorambucil
(16.4 mmol, 1.0 equiv.) in DCM (25.0 mL, 5.0 vol) and a catalytic
amount of N, N-dimethylformamide. The reaction mixture was
stirred at ambient temperature for 2e3 h, after which excess oxalyl
chloride and DCM were removed under reduced pressure. The
chlorambucil acid chloride that was obtained was a pale green solid
in quantitative yield, which was used as such for the synthesis of
Compounds 2aec.
4.1.3. 4-(4-(Bis(2-chloroethyl)amino)phenyl)butan-1-ol (3)
Compound 1 (15.5 mmol, 1.0 equiv.) was dissolved in DCM
(125 mL) and methanol (75 mL, 3 vol) was slowly added over a
period of 1 h at 15e20 C. The reaction mixture was stirred at
ambient temperature for 2 h. The reaction mixture was concen-
trated and the residue was dissolved in ethyl acetate (125mL, 5 vol)
and washed successively with a 5% aq. NaHCO3. Evaporation of the
solvent under reduced pressure resulted in the chlorambucil
methyl ester (16.4mmol,1.0 equiv.) in 95% yield as a light brown oil,
which was added to a suspension of lithium aluminium hydride
(32.8mmol, 2 equiv.) in anhydrous THF (100mL, 4 vol) at 0e5 C for
a period of 1 h. The reaction mixture was thereafter allowed to stir
at ambient temperature for 2e3 h. Next, the reaction mixture was
cooled to 0e5 C and quenched slowly with ethyl acetate (250 mL,elivering cytotoxic drugs towards CAIX expressing cells: A concept of
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ﬁltered through celite and ethyl acetate (50 mL, 2 vol) was used to
wash the celite bed. The organic layer was washed with water
(100 mL, 4 vol), dried over anhydrous Na2SO4, and ﬁltered. Evap-
oration of the solvent under reduced pressure resulted in 99% yield
of the crude alcohol as a pale yellow oil, which was used in the next
step.
4.1.4. 4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl
carbonochloridate (4)
DMF (1.4 g) and sodium carbonate (75.79 mmol, 1.1 equiv.) were
added to a solution of triphosgene (37.89 mmol, 0.55 equiv.) in
toluene (300 mL, 15 vol) at ambient temperature. The reaction
mixture was cooled to 0e5 C and maintained at the same tem-
perature for 30 min. Next, a solution of 3 (68.9 mmol, 1.0 equiv.) in
toluene (100 mL, 5 vol) was added to the stirred reaction mixture at
0e5 C during 30 min. This reaction mixture was stirred for
4e5 h at room temperature. The reaction mixture was ﬁltered
thereafter and the solid was washed with toluene (100 mL, 5 vol).
Evaporation of the solvent under reduced pressure resulted in the
chloroformate 4 with a 64% yield as a yellow viscous liquid, which
was used for the synthesis of carbamates (compounds 5aec).
4.1.5. General procedure for the preparation of compounds (2aec
and 5aec)
To a solution of aminoalkylbenzene sulfonamide (1.0 equiv.) in
acetonitrile (225 mL, 15 vol) and N,N-diisopropylethylamine (2.5
equiv.) a solution of compound 1 (2aec) or compound 4 (5aec) (1.0
equiv.) in acetonitrile (75 mL, 5 vol) was added over a period of 1 h
and stirred overnight at ambient temperature. After completion,
the reaction mixture was concentrated and the residue obtained
was dissolved in ethyl acetate (150 mL, 10 vol). The organic layer
was successively washed with 2 N HCl solution (100 mL  2) in
water, dried over anhydrous Na2SO4, and ﬁltered. After evaporation
of the solvent under reduced pressure a pale yellow solid was ob-
tained as a crude product. This crude product was puriﬁed with
column chromatography using a silica gel (40% ethyl acetate in
hexane) to obtain compound 2aec and 5aec in a 51e87% yield.
4.1.6. General procedure for amination of 3-Chlorobenzotriazine-
1,4-di-N-oxides (7 and 10)
4-(2-Aminoethyl) benzene sulfonamide (8.25 mmol, 3.0 equiv.)
was added to a stirring solution of 3 chlorobenzotriazine-1,4-di-N-
oxide (2.75 mmol, 1.0 equiv.) in dimethoxyethane (30 mL) and the
mixture was stirred overnight at reﬂux temperature. The next day
mixture was cooled to room temperature and concentrated under
vacuum, after which the residue was dissolved in ammonium hy-
droxide solution and extracted with ethyl acetate. The organic layer
was dried over Na2SO4, ﬁltered and concentrated under vacuum.
The residue was puriﬁed by chromatography using a silica gel with
methylene chloride-methanol 98:2 v-v as an eluent to obtain the
expected compound as a yellow powder with an 85e94% yield.
4.1.7. General procedure for oxidation (8 and 11)
Hydrogen peroxide (12.9 mmol, 10 equiv.) was added dropwise
to a stirred solution of triﬂuoroacetic anhydride (12.9 mmol, 10
equiv.) in DCM at 0 C. This reaction mixture was stirred at 0 C for
5 min, warmed to room temperature for 10 min, and cooled to 5 C.
Next, the mixture was added to a stirred solution of mono oxide
(1.29 mmol, 1.0 equiv.) in DCM at 0 C and stirred at room tem-
perature for 2e3 days. The reaction mixture was carefully diluted
with water and basiﬁed with aqueous NH4OH and extracted with
CHCl3. The organic fraction was dried over anhydrous Na2SO4,
ﬁltered and evaporated to obtain the residue. This residue was
puriﬁed by chromatography using a silica gel with methylenePlease cite this article in press as: S.J.A. van Kuijk, et al., New approach of d
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compound as an orange red powder with a 46e96% yield.4.1.8. General procedure for synthesis of ATRi derivatives (12 and
13)
A solution of VE-821 or VE-822 (0.54 mmol, 1.0 equiv.) and
triethylamine (1.62 mmol, 3.0 equiv.) in 10 mL of methylene chlo-
ride was added to a mixture of chlorosulfonyl isocyanate
(0.68 mmol, 1.2 equiv.) and tert-butanol (0.648 mmol, 1.2 equiv.) in
2 mL of methylene chloride. The mixture was stirred at room
temperature for 1.0 h, diluted with ethyl acetate, and washed with
water. The organic layer was then dried over anhydrous Na2SO4,
ﬁltered and concentrated under vacuum. The residue was puriﬁed
by chromatography with a silica gel and methylene chloride-
methanol 98:2 as an eluent. This intermediate was thereafter
diluted in a solution of triﬂuoro acetic acid in methylene chloride
(20% vol.) and stirred at room temperature for 6 h. Next, the
mixture was concentrated under vacuum and co-evaporated with
diethyl ether multiple times to obtain the expected compoundwith
a 58e65% yield.4.1.9. General procedure for synthesis of temozolomide derivatives
To a slurry of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d]
[1,2,3,5] tetrazine-8-carboxylic acid (1.0 mmol, 1.0 equiv.) in DCM,
BOP (1.0 mmol, 1.0 equiv.), amine (1.1 mmol, 1.1 equiv.) and trie-
thylamine (2.5 mmol, 2.5 equiv.) were added. This reaction mixture
was stirred overnight at room temperature and ﬁltered to obtain
the expected compounds with a 41e95% yield.4.1.10. 4-(4-(Bis(2-chloroethyl)amino)phenyl)-N-(4-
sulfamoylphenyl)butanamide (2a)
mp: 155e157 C; 1H NMR (400 MHz, DMSO-d6), d 10.22 (s, 1H),
7.73 (d, J ¼ 4.4, 4H), 7.23 (s, 2H), 7.05 (d, J ¼ 8.7, 2H), 6.67 (d, J ¼ 8.7,
2H), 3.70 (d, J ¼ 8.6, 8H), 2.54e2.50 (m, 2H), 2.34 (t, J ¼ 8.6, 2H),
1.90e1.78 (m, 2H); 13C NMR (101 MHz, DMSO-d6), d 171.68, 144.46,
142.23, 138.03, 129.53, 126.65, 118.51, 111.90, 52.22, 41.17, 35.84,
33.54, 26.87; MS (ESIþ) m/z 458.11 [MþH]þ, 460.10 [Mþ2]þ. HRMS
(ESIþ) [MþH]þ calculated for [C20H26N3O3SCl2]þ: 458.1072, found:
458.1075.4.1.11. 4 -(4-(bis(2-chloroethyl)amino)phenyl)-N-(4-
sulfamoylbenzyl)butanamide (2b)
mp: 130e132 C; 1H NMR (400MHz, DMSO-d6), d 8.41 (t, J¼ 5.9,
1H), 7.76 (d, J ¼ 8.3, 2H), 7.41 (d, J ¼ 8.3, 2H), 7.31 (s, 2H), 7.02 (d,
J ¼ 8.6, 2H), 6.66 (d, J ¼ 8.6, 2H), 4.31 (d, J ¼ 5.9, 2H), 3.69 (s, 8H),
2.45 (t, J ¼ 7.5, 2H), 2.15 (t, J ¼ 7.5, 2H), 1.82e0.72 (m, 2H); 13C NMR
(101 MHz, DMSO-d6), d 172.15, 144.42, 143.92, 142.54, 129.86,
129.33,127.46,125.68,111.89, 52.22, 41.67, 41.17, 34.84, 33.66, 27.39;
MS (ESIþ) m/z 472.12 [MþH]þ, 474.12 [Mþ2]þ. HRMS (ESIþ)
[MþH]þ calculated for [C21H28N3O3SCl2]þ: 472.1228, found:
472.1236.4.1.12. 4-(4-(Bis(2-chloroethyl)amino)phenyl)-N-(4-
sulfamoylphenethyl)butanamide(2c)
mp: 108e110 C; 1H NMR (400 MHz, DMSO-d6), d 7.89 (t, J¼ 5.6,
1H), 7.74 (d, J ¼ 8.3, 2H), 7.38 (d, J ¼ 8.3, 2H), 7.30 (s, 2H), 7.00 (d,
J ¼ 8.6, 2H), 6.66 (d, J ¼ 8.6, 2H), 3.70 (d, J ¼ 8.9, 8H), 3.29 (dd,
J ¼ 13.0, 5.6, 2H), 2.78 (t, J ¼ 7.5, 2H), 2.41 (t, J ¼ 7.5, 2H), 2.08e1.98
(m, 2H), 1.76e1.65 (m, 2H); 13C NMR (101 MHz, DMSO-d6), d 171.95,
144.39, 143.80, 142.01, 129.89, 129.21, 125.67, 111.87, 52.23, 41.17,
34.87, 33.61, 27.32; MS (ESIþ) m/z 486.14 [MþH]þ, 488.14 [Mþ2]þ.
HRMS (ESIþ) [MþH]þ calculated for [C22H30N3O3SCl2]þ: 486.1385,
found 486.1387.elivering cytotoxic drugs towards CAIX expressing cells: A concept of
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sulfamoylphenyl)carbamate(5a)
mp: 156e158 C; 1H NMR (400 MHz, DMSO-d6), d 10.01 (s, 1H),
7.76e7.69 (m, 2H), 7.64e7.56 (m, 2H), 7.22 (s, 2H), 7.04 (d, J ¼ 8.7,
2H), 6.66 (d, J ¼ 8.7, 2H), 4.12 (t, J ¼ 6.0, 2H), 3.77e3.63 (m, 8H),
1.70e1.54 (m, 4H); 13C NMR (101 MHz, DMSO-d6), d 153.50, 144.40,
142.34, 137.48, 130.06, 129.30, 126.77, 117.50, 111.89, 64.43, 52.22,
41.17, 33.68, 28.09, 27.62; MS (ESIþ) m/z 488.12 [MþH]þ, 490.12
[Mþ2]þ. HRMS (ESIþ) [MþH]þ calculated for [C21H28N3O4SCl2]þ:
488.1178, found: 488.1184.
4.1.14. 4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl (4-
sulfamoylbenzyl)carbamate(5b)
mp: 98e100 C; 1H NMR (400 MHz, DMSO-d6), d 7.76 (t, J ¼ 8.5,
3H), 7.41 (d, J ¼ 8.5, 2H), 7.31 (s, 2H), 7.02 (d, J ¼ 8.6, 2H), 6.66 (d,
J¼ 8.6, 2H), 4.23 (d, J¼ 6.1, 2H), 3.98 (s, 2H), 3.75e3.63 (m, 8H), 2.47
(s, 2H), 1.55 (m, 4H); 13C NMR (101 MHz, DMSO-d6), d 156.63,
144.37, 143.97, 142.61, 130.13, 129.26, 127.27, 125.70, 111.88, 63.84,
52.23, 43.37, 41.18, 33.68, 28.31, 27.64; MS (ESIþ) m/z 502.13
[MþH]þ, 504.13 [Mþ2]þ. HRMS (ESIþ) [MþH]þ calculated for
[C22H30N3O4SCl2]þ: 502.1334, found: 502.1338.
4.1.15. 4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl (4-
sulfamoylphenethyl)carbamate(5c)
mp: 100e102 C; 1H NMR (400 MHz, DMSO-d6), d 7.77e7.70 (m,
2H), 7.37 (d, J ¼ 8.2, 2H), 7.30 (s, 2H), 7.19 (t, J ¼ 5.5, 1H), 7.02 (d,
J ¼ 8.6, 2H), 6.66 (d, J ¼ 8.6, 2H), 3.94 (d, J ¼ 5.5, 2H), 3.69 (s, 8H),
3.21 (dd, J ¼ 13.3, 6.6, 2H), 2.76 (dd, J ¼ 16.9, 9.8, 2H), 2.46 (s, 2H),
1.52 (s, 4H); 13C NMR (101 MHz, DMSO-d6), d 156.30, 144.37, 143.58,
142.03, 130.15, 129.19, 125.67, 111.88, 63.51, 52.23, 41.28, 35.09,
33.67, 28.32, 27.63; MS (ESIþ) m/z 516.15 [MþH]þ, 518.15 [Mþ2]þ.
HRMS (ESIþ) [MþH]þ calculated for [C23H32N3O4SCl2]þ: 516.1491,
found: 516.1490.
4.1.16. 3-(4-Sulfamoylphenethylamino) benzo [e][1,2,4] triazine 1-
oxide (7)
Compound 7 was synthesized from 6 by a general amination
method and resulted in a yellow solid with a yield of 94%. mp:
250e252 C; 1H NMR (400 MHz, DMSO-d6), d 8.15 (s, 1H), 8.13 (s,
1H), 8.03 (s, 1H), 7.82e7.71 (m, 3H), 7.60 (d, J ¼ 8.0, 1H), 7.47 (d,
J¼ 8.0, 2H), 7.38e7.30 (m,1H), 7.28 (s, 2H), 3.60 (d, J¼ 6.2, 2H), 3.01
(dd, J ¼ 6.2, 2H); 13C NMR (101 MHz, DMSO-d6) d 158.80, 143.70,
142.07, 135.76, 129.25, 125.92, 124.66, 119.93, 41.92, 34.09; MS
(ESIþ) m/z 346.10 [MþH]þ. HRMS (ESIþ) [MþH]þ calculated for
[C15H16N5O3S]þ: 346.0974, found: 346.0973.
4.1.17. 3-((4-Sulfamoylphenethyl)amino)benzo[e][1,2,4]triazine 1,4-
dioxide (8)
Compound 8 was synthesized from 7 by a general oxidation
method, resulting in an orange red solid with a yield of 96%. mp:
210e212 C; 1H NMR (400 MHz, DMSO-d6), d 8.31 (t, J ¼ 6.1, 1H),
8.22 (d, J ¼ 8.1, 1H), 8.13 (d, J ¼ 8.1, 1H), 7.97e7.89 (m, 1H), 7.75 (d,
J ¼ 8.3, 2H), 7.61e7.53 (m, 1H), 7.47 (d, J ¼ 8.3, 2H), 7.29 (s, 2H), 3.67
(dd, J ¼ 7.2, 6.1, 2H), 3.03 (t, J ¼ 7.2, 2H); 13C NMR (101 MHz, DMSO-
d6), d 149.67, 143.19, 142.16, 138.19, 135.48, 130.07, 129.26, 127.04,
125.71, 121.13, 116.89, 41.76, 34.18; MS (ESIþ) m/z 362.09 [MþH]þ.
HRMS (ESIþ) [MþH]þ calculated for [C15H16N5O4S]þ: 362.0923,
found: 362.0928.
4.1.18. 3-(4-Sulfamoylphenethylamino)-7,8-dihydro-6H-indeno
[5,6-e][1,2,4] triazine 1-oxide (10)
Compound 10 was synthesized from 9 by using a general ami-
nation method, which resulted in a yellow solid with a 85% yield.
mp: 238e240 C; 1H NMR (400 MHz, DMSO-d6), d 7.95 (s, 1H), 7.82
(s, 1H), 7.74 (t, J¼ 10.0, 2H), 7.49e7.39 (m, 3H), 7.28 (s, 2H), 3.57 (dd,Please cite this article in press as: S.J.A. van Kuijk, et al., New approach of d
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(101 MHz, DMSO-d6), d 157.56, 153.64, 142.79, 141.97,
130.10e127.99, 125.35, 112.78, 41.77, 32.35, 31.60, 25.25; MS (ESIþ)
m/z 386.13 [MþH]þ. HRMS (ESIþ) [MþH]þ calculated for
[C18H20N5O3S]þ: 386.1287, found: 386.1291.
4.1.19. 3-((4-Sulfamoylphenethyl) amino)-7,8-dihydro-6H-indeno
[5,6-e][1,2,4] triazine 1,4-dioxide (11)
Compound 11 was synthesized from 10 by using a general
oxidation method resulting in an orange red solid with a yield of
46%. mp: 218e220 C; 1H NMR (400 MHz, DMSO-d6), d 8.19 (s, 1H),
7.98 (d, J¼ 24.2, 2H), 7.75 (d, J¼ 7.8, 2H), 7.46 (d, J¼ 7.7, 2H), 7.29 (s,
2H), 3.65 (d, J ¼ 6.2, 2H), 3.12e2.92 (m, 6H), 2.17e1.99 (m, 2H); 13C
NMR (101 MHz, DMSO-d6), d 154.56, 149.25, 145.07, 143.22, 142.15,
129.23, 125.71, 41.76, 32.74, 31.80, 25.24; MS (ESIþ) m/z 402.12
[MþH]þ. HRMS (ESIþ) [MþH]þ calculated for [C18H20N5O4S]þ:
402.1236, found: 402.1234.
4.1.20. 6-(4-(Methylsulfonyl)phenyl)-N-phenyl-3-
(sulfamoylamino)pyrazine-2-carboxamide (12)
Compound 12 was synthesized from commercially purchased
VE-821 by using the general procedure described above, which
resulted in a yellow solid with an overall yield of 58%. mp:
233e235 C; 1H NMR (400 MHz, DMSO-d6), d 11.27 (s, 1H), 10.82 (s,
1H), 9.28 (s, 1H), 8.64 (d, J ¼ 8.6, 2H), 8.08 (d, J ¼ 8.6, 2H), 7.83e7.76
(m, 2H), 7.68 (s, 2H), 7.48e7.39 (m, 2H), 7.23 (dd, J ¼ 14.0, 6.6, 1H),
3.30 (s, 3H); 13C NMR (101 MHz, DMSO-d6), d 164.59e163.27,
149.32e147.73, 144.46e143.38, 141.16, 139.57, 137.17e136.45,
128.69, 127.46,125.15, 122.08, 43.46; MS (ESIþ)m/z 448.07 [MþH]þ.
HRMS (ESIþ) [MþH]þ calculated for [C18H18N5O2S2]þ: 448.0749,
found: 448.0748.
4.1.21. 5-(4-(Isopropylsulfonyl) phenyl)-3-(3-(4-((methylamino)
methyl) phenyl) isoxazol-5-yl) pyrazin-2-carboxamide (13)
Compound 13 was synthesized from commercially purchased
VE-822 by using the general procedure described above, which
resulted in a yellow solid with an overall yield of 65%. mp:
242e244 C; 1H NMR (400 MHz, DMSO-d6), d 8.94 (s, 1H), 8.38 (d,
J¼ 8.5, 2H), 8.02 (d, J¼ 8.2, 2H), 7.93 (d, J¼ 8.5, 2H), 7.79 (s,1H), 7.54
(d, J ¼ 8.2, 2H), 7.20 (s, 2H), 6.96 (s, 2H), 4.17 (s, 2H), 3.54e3.38 (m,
1H), 2.58 (s, 3H), 1.17 (t, J¼ 14.1, 6H); 13C NMR (101MHz, DMSO-d6),
d 167.67, 162.00, 151.75, 142.47, 141.04, 139.53, 137.62, 135.78,
129.00, 127.17, 125.69, 124.47, 102.16, 54.22, 53.49, 34.94, 15.19; MS
(ESIþ) m/z 543.15 [MþH]þ. HRMS (ESIþ) [MþH]þ calculated for
[C24H27N6O5S2]þ: 543.1484, found: 543.1484.
4.1.22. 3-Methyl-4-oxo-N-(4-sulfamoylphenethyl)-3,4-
dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (15a)
Compound 15a was synthesized from 14 by reacting it with 4-
(2-aminoethyl) benzene sulfonamide using the general procedure
for synthesizing temozolomide derivatives described above. This
reaction resulted in a white solid with a yield of 50%. mp:
195e197 C; 1H NMR (400 MHz, DMSO-d6), d 8.83 (s, 1H), 8.58 (t,
J¼ 5.9,1H), 7.74 (d, J¼ 8.3, 2H), 7.44 (d, J¼ 8.3, 2H), 7.30 (s, 2H), 3.86
(s, 3H), 3.58 (dd, J ¼ 13.4, 6.8, 2H), 2.96 (t, J ¼ 7.1, 2H); 13C NMR
(101 MHz, DMSO-d6), d 159.67, 143.64, 142.05, 139.20, 134.45,
130.30, 129.14, 128.46, 125.73, 36.16, 34.78; MS (ESIþ) m/z 378.10
[MþH]þ. HRMS (ESIþ) [MþH]þ calculated for [C14H16N7O4S]þ:
378.0984, found: 378.0986.
4.1.23. 3-Methyl-4-oxo-N-(sulfamoyloxy)-3,4-dihydroimidazo[5,1-
d][1,2,3,5]tetrazine-8-carboxamide (15b)
Compound 15b was synthesized from 14 by reacting it with
aminoxysulfonamide using the general procedure for synthesizing
temozolomide derivatives described above. This reaction resultedelivering cytotoxic drugs towards CAIX expressing cells: A concept of
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(400 MHz, DMSO-d6), d 8.81 (s, 1H), 7.80 (s, 1H), 7.67 (s, 1H), 7.30 (s,
2H), 3.86 (s, 3H); 13C NMR (101 MHz, DMSO-d6) d 161.51, 139.16,
134.57, 130.51, 128.37, 45.72.
4.1.24. 3-Methyl-4-oxo-N-(4-sulfamoylbenzyl)-3,4-dihydroimidazo
[5,1-d][1,2,3,5]tetrazine-8-carboxamide (15c)
Compound 15c was synthesized from 14 by reacting it with 4-
(aminomethyl) benzene sulfonamide hydrochloride using the
general procedure for synthesizing temozolomide derivatives
described above. This reaction resulted in a white solid with a yield
of 88%. mp: 185e187 C; 1H NMR (400 MHz, DMSO-d6) d 9.20 (t,
J¼ 6.2,1H), 8.87 (s, 1H), 7.77 (d, J¼ 8.3, 2H), 7.50 (d, J¼ 8.3, 2H), 7.31
(s, 2H), 4.55 (d, J¼ 6.3, 2H), 3.87 (s, 3H); 13C NMR (101 MHz, DMSO-
d6), d 159.96, 143.85, 142.63, 142.63, 138.96, 134.69, 130.11, 129.28,
128.62, 127.68, 125.77, 41.94, 36.23; MS (ESIþ) m/z 364.08 [MþH]þ.
HRMS (ESIþ) [MþH]þ calculated for [C13H14N7O4S]þ: 364.0828,
found: 364.0826.
4.1.25. 3-Methyl-4-oxo-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-3,4-
dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (15d)
Compound 15d was synthesized from 14 by reacting it with 5-
amino-1, 3,4-thiadiazole-2-sulfonamide hydrochloride using the
general procedure for synthesizing temozolomide derivatives
described above. This reaction resulted in a light yellow solid with a
yield of 95%. mp: 128e130 C; 1H NMR (400 MHz, DMSO-d6), d 8.63
(s, 1H), 8.06 (s, 1H), 7.81 (s, 1H), 7.35 (s, 2H), 3.83 (s, 3H); 13C NMR
(101MHz, DMSO-d6), d 171.73, 170.89, 165.39, 161.04, 157.91, 139.53,
134.24,127.88; MS (ESIþ)m/z 358.01 [MþH]þ. HRMS (ESIþ) [MþH]þ
calculated for [C8H8N9O4S2]þ: 358.0141, found: 358.0140.
4.1.26. Synthesis of 4-(2-(3-carbamimidoylguanidino)ethyl)
benzenesulfonamide hydrochloride salt (18)
4-(2-Aminoethyl)benzenesulfonamide 16 (0.5g, 1.0 equiv.) and
cyanoguanidine 17 (0.21g, 1.0 equiv.) were suspended in n-butanol
(5.0 mL) and treated with a 6.0 M aqueous hydrochloric acid so-
lution (1.0 equiv., 0.4 mL). The mixture was treated at 100 C
overnight and the solvents were removed under vacuum. The
residue was thereafter crystallized from isopropyl alcohol (IPA) to
obtain compound 18 as a white solid with a 75% yield. mp:
154e159 C; 1H NMR (400MHz, DMSO-d6), d 7.87 (d, 2H, J¼ 8.4, Ar-
H), 7.82 (brs, 2H, exchangeable with D2O), 7.50 (d, 2H, J¼ 8.4, Ar-H),
7.38 (brs, 1H, exchangeable with D2O), 6.62 (brs, 2H, exchangeable
with D2O), 3.15 (t, 2H, J ¼ 6.7), 2.98 (t, 2H, J ¼ 6.7); 13C NMR
(101 MHz, DMSO-d6), d 164.0, 143.7, 142.0, 130.3, 127.0, 119.3, 61.4,
34.1; MS (ESIþ) m/z 285.11 [MþH]þ.
4.2. CA inhibition assays
To measure the CA-catalyzed CO2 hydration activity an Applied
Photophysics stopped-ﬂow instrument was used [61]. To maintain
ionic strength Na2SO4 (20 mM) was used with HEPES (20 mM, pH
7.5) as a buffer and Phenol red (0.2 mM) as an indicator working at
the maximum absorbance of 557 nm, which was used to follow the
initial rates of the CA-catalyzed CO2 hydration for a duration of
10e100 s. To determine the kinetic parameters and inhibition
constants varying CO2 concentrations were included (1.7e17 mM).
Initial velocity was assayed with at least six traces of the initial
5e10% of the reaction for each compound. Compounds were dis-
solved in distilled-deionized water (0.01 nM). The combined
enzyme solutions and compounds were incubated for 15 min at
room temperature to allow for the E-I complex formation prior to
measurements. The nonlinear least-squares method of PRISM 3
was used to estimate the inhibition constants and the mean of
three independent estimations is reported. The CA isoformsPlease cite this article in press as: S.J.A. van Kuijk, et al., New approach of d
dual-target drugs, European Journal of Medicinal Chemistry (2016), httpincluded are recombinant proteins obtained in house.
4.3. Biological assays
4.3.1. Cells
All cell lines used were cultured in DMEM supplemented with
10% fetal bovine serum. Canine kidney epithelial MDCK cells over-
expressing human CAIX (CAIXþ) or a scrambled control vector
(CAIX) have been described before [37] and [44]. The HCT116
constitutive CAIX knockdown cell line and its scrambled control
have also been described before and were kindly provided by
Professor Adrien Harris (Weatherall Institute of Molecular Medi-
cine, University of Oxford, John Radcliffe hospital, Oxford, UK) [24]
[28], and [62]. Cells were exposed to hypoxic or anoxic conditions
in a hypoxic chamber (MACS VA500 microaerophilic workstation,
DonWhitley Scientiﬁc, UK) with 0.2 or0.02% O2, respectively, and
5% CO2 and residual N2 to upregulate and activate CAIX. Normoxic
cells were grown in normal incubators with 21% O2, 5% CO2 at 37 C.
4.3.2. Cell viability assays
The efﬁcacy of the cytotoxic derivatives was compared to their
respective parental compounds in cell viability assays using ala-
marBlue® (Invitrogen). In short, MDCK cells were seeded in 96-well
plates and allowed to attach overnight. The next day plates were
exposed to hypoxia and DMEM was replaced with pre-incubated
hypoxic DMEM. In contrast, testing the ATRi was performed in
anoxic conditions to decrease the radiosensitivity of the cells. In
parallel normoxic 96-well plates were incubated in normal in-
cubators with 21% O2 and 5% CO2. Compounds were dissolved in
DMSO (0.5%, Sigma-Aldrich) and ﬁnal concentrations were made
with pre-incubated hypoxic or normoxic DMEM and added to the
wells after 24 h of exposure. To test the ATR inhibitors cells were
exposed to the compounds 1 h prior to irradiation and the 96-well
plates were irradiated (225 kV Philips X-ray tube) with 2 Gy (nor-
moxia) or 4 Gy (anoxia). Cells were exposed to compounds for a
total of 2 h for chlorambucil and tirapazamine, or 72 h for temo-
zolomide and the ATR inhibitors, after which mediumwas washed
off and replaced with fresh medium. For chlorambucil, tirapaz-
amine, and ATR inhibitor derivatives cells were allowed to grow for
an additional 72 h under normoxic conditions prior to measure-
ment, whereas cells exposed to temozolomide derivatives
remained in hypoxic conditions prior to measurement. Cells were
allowed to convert alamarBlue® for 2 h during normoxic condi-
tions, which corresponds with their metabolic function and is a
measure for cell viability.
4.3.3. Clonogenic assays
Clonogenic survival of MDCK cells was determined with high
cell numbers to allow for CAIX-dependent extracellular acidiﬁca-
tion [44]. These cells were exposed to temozolomide or 15b for 24 h
during normoxic or hypoxic conditions after which cells were
trypsinized and reseeded in triplicate with known cell numbers.
Cells were allowed to grow for 7 days to form colonies that were
quantiﬁed after staining and ﬁxation with 0.4% methylene blue in
70% ethanol. Surviving fraction was normalized to vehicle (0.5%
DMSO).
4.3.4. Basal respiration measurements
Oxygen Consumption Rates (OCR) were determined using the
Seahorse XF96 extracellular Flux analyzer (Agilent Technologies).
Cells were seeded in a XF96 cell plate with normal growth medium
at an optimized cell density of 1.5  104 cells/well. Plates were
placed in a 5% CO2 incubator at 37 C in order to let the cells attach.
Subsequently cells were incubated for 18 h under hypoxic condi-
tions (0.2% O2). Culture medium was exchanged with DMEMelivering cytotoxic drugs towards CAIX expressing cells: A concept of
://dx.doi.org/10.1016/j.ejmech.2016.10.037
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sodiumpyruvate (GIBCO, Thermo Fisher) 60 min prior to the assay
and plates were placed in a CO2-free incubator at 37 C. Prior to the
ﬁrst injection, baseline OCR was determined using a mixing period
of 5 min and a measurement period of 3 min followed by 3 loops of
mixing and measuring for 3 min each. Medium containing vehicle
(PBS, Lonza), Phenformin Hydrochloride (Sigma-Aldrich), or the
CAIXi conjugated phenformin derivative 18 were injected followed
by several mixing and measurements cycles. Subsequently cells
were washed with PBS and lysed in a 0.05% SDS (Sigma-Aldrich)
solution. Protein quantiﬁcation for normalization purposes was
performed using Pierce™ BCA Protein Assay Kit (Thermo Fisher).
4.3.5. Western blot
To validate CAIX expression in the genetically modiﬁed cell lines
protein immunoblotting was performed after 24 h of hypoxia
exposure (0.2% O2) as described previously [43]. Primary antibodies
used included the anti-CAIX M75 antibody (kindly provided by
Professor Silvia Pastorekova, Institute of Virology, Slovak Academy
of Science, Slovak Republic), and anti-b-actin (MP Biomedicals,
#691001) as a reference protein.
4.3.6. Statistical analyses
GraphPad Prism (version 5.03) was used for all statistical ana-
lyses. For the cytotoxic compounds IC50 values were estimated with
the curve of the log(inhibitor) vs. normalized response (Variable
slope). Means between groups were compared using unpaired t-
tests, where p < 0.05 indicated statistical signiﬁcance.
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